Stage IIC Melanoma Clinical Trial
Official title:
Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection
This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma. Biological therapies, such as sargramostim, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether sargramostim is more effective than hypertonic saline in treating patients with stage IB-II melanoma undergoing sentinel lymph node biopsy.
PRIMARY OBJECTIVES:
I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes
are reversible.
II. To determine if the restoration of the morphology or phenotype of sentinel lymph nodes
results in diminished regional tumor burden.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sargramostim subcutaneously (SC) 3-5 days prior to undergoing
sentinel lymph node biopsy.
ARM II: Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph
node biopsy.
After completion of study treatment, patients are followed up for 30 days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Completed |
NCT00085189 -
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01898403 -
Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
|
N/A | |
Completed |
NCT00089063 -
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
|
Phase 2 | |
Completed |
NCT00669019 -
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00003895 -
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
|
Phase 2 |